论文部分内容阅读
目的:探讨心力衰竭患者中N-端脑钠肽前体的变化和意义。方法:将受试对象分为心力衰竭组和非心力衰竭组,选择我院收治的心功能II级7例、IV级8例(心功能按NYHA的标准分级)共15例为心衰组,无器质性心脏病者10例为非心衰组。采用电化学发光免疫分析仪测定患者血浆NT-Ppro BNP水平,彩色多普勒超声诊断仪进行心脏超声检查测量左心室射血分数(LVEF)。结果:心衰组患者血浆NT-Pro BNP水平显著高于非心衰组,有显著性差异,两组左心室射血分数(LVEF)比较有显著性差异;心功能IV级组患者血浆NT-Ppro BNP水平显著高于心功能II级组,有显著性差异。结论:NT-Ppro BNP可作为判断患者是否有心功能不全,左心室功能受损严重程度和治疗效果的评价指标。
Objective: To investigate the changes and significance of N-terminal pro-brain natriuretic peptide precursor in patients with heart failure. Methods: The subjects were divided into heart failure group and non-heart failure group. Seven patients with grade II in our hospital and 8 patients with grade IV (NYHA standard classification) 10 cases without organic heart disease were non-heart failure group. The levels of NT-proBNP in plasma were measured by electrochemiluminescence immunoassay. The left ventricular ejection fraction (LVEF) was measured by color Doppler sonography. Results: The plasma levels of NT-Pro BNP in patients with heart failure were significantly higher than those in non-heart failure patients. There was significant difference between the two groups in the left ventricular ejection fraction (LVEF) Ppro BNP levels were significantly higher than those of the cardiac function level II group, with significant differences. Conclusion: NT-Ppro BNP can be used as an index to judge whether patients have cardiac insufficiency, severity of left ventricular dysfunction and therapeutic effect.